Skip to content

Home
Insights
Brochures
Careers
About us
News

Home
Insights
Brochures
Careers
About us
News

Uncategorized

INVESTOR CALENDER OF THE WEEK March 24,2026 To March 26,2026 BNP Paribas Exane Healthcare Conference March 24 Goldman Sachs Biopharma Innovation Summit March 25 March 26 All logos and trademarks remain the intellectual properties of their respective owners

Attention Stay up to date with the latest investor calls by checking out our calendar for the week of March 24,2026 To March 26,2026

Uncategorized / YASHASWINI N

Attention Stay up to date with the latest investor calls by checking out our calendar for the week of March 24,2026 To March 26,2026 Read More »

Highlights from the Week of 16th March 2026 - 23rd March 2026 ( FDA, Approval ) FDA grants approval to Rhythm Pharmaceuticals' IMCIVREE as a label expansion to treat acquired hypothalamic obesity in patients aged 4 years and older ( FDA, Approval ) Novo Nordisk's WEGOVY HD 7.2 mg gains FDA approval to reduce excess body weight and maintain long‑term weight reduction, based on results from the STEP UP trial ( FDA, Approval ) Johnson & Johnson receives FDA approval for ICOTYDE, an IL-23R-targeted oral peptide for treating moderate-to-severe plaque psoriasis ( FDA, Approval ) FDA approves GSK's LYNAVOY, an IBAT inhibitor, to treat cholestatic pruritus in patients with primary biliary cholangitis Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 16th March 2026 – 23rd March 2026 in the world of pharma and healthcare!

Uncategorized / YASHASWINI N

Highlights from the Week of 16th March 2026 – 23rd March 2026 in the world of pharma and healthcare! Read More »

INVESTOR CALENDER OF THE WEEK 18-Feb-2026 Citi's 2026 Virtual Oncology leadership Summit Fourth-Quarter and Full-Year 2025 Earnings Presentation Feb 18 Feb 18 AMGEN BAUSCH Health Visit our website for more updates | www.vyuhpharma.com All logos and trademarks remain the intellectual properties of their respective owners

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of 18- Feb-2026💻

Uncategorized / YASHASWINI N

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of 18- Feb-2026💻 Read More »

VYUHPHARMA Highlights from the Week of 9th February - 16th February MERCK 百奥泰 BIO-THERA AMGEN FDA approves Merck's KEYTRUDA and KEYTRUDA QLEX for certain patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, who have received one or two prior systemic treatment regimens European Commission grants marketing authorization for Bio-Thera's GOTENFIA, a biosimilar referencing SIMPONI, for the treatment of various types of arthritis European Commission approves Amgen's UPLIZNA for the treatment of adult patients with generalized myasthenia gravis who are anti-AChR and anti-MuSK antibody positive (FDA, Approval) (EU, Approval) (EU, Approval) Pg 1/4 All logos and trademarks remain the intellectual properties of their respective owners

📢Highlights from the Week of 9th February – 16th February in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢Highlights from the Week of 9th February – 16th February in the world of pharma and healthcare! 🗞️👀 Read More »

Q4 2025 Earning conference Call Feb 10,2026 To Feb 13,2026 Feb 10 Feb 12 Feb 13 All logos and trademarks remain the intellectual properties of their respective owners

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of Feb 10,2026 To Feb 13,2026💻

Uncategorized / YASHASWINI N

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of Feb 10,2026 To Feb 13,2026💻 Read More »

Highlights from the Week of 02 February 2026 - 09 February 2026 ( FDA, Approval ) FDA approves Exelixis' zanzalintinib in combination with atezolizumab for the treatment of adult patients with previously treated metastatic colorectal cancer, with a PDUFA date of December 3, 2026 ( EU, Approval ) The European Commission approves GSK's NUCALA as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease based on the data from Phase III MATINEE trial ( NMPA, Approval ) NMPA approves Bayer's NUBEQA in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer based on the Phase III ARANOTE trial ( NMPA, Approval ) NMPA approves a new indication of Kelun-Biotech's sacituzumab tirumotecan to treat unresectable or metastatic HR+/HER2- breast cancer who previously received endocrine therapy and at least one line of chemotherapy Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners

📢Highlights from the Week of 02 February 2026 – 09 February 2026 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢Highlights from the Week of 02 February 2026 – 09 February 2026 in the world of pharma and healthcare! 🗞️👀 Read More »

Q4 2025 Earning conference Call Jan 28,2025 To Jan 30,2025 Jan 28 Jan 29 Jan 30 All logos and trademarks remain the intellectual properties of their respective owners

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of Jan 28,2026 To Jan 30,2026 💻

Uncategorized / YASHASWINI N

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of Jan 28,2026 To Jan 30,2026 💻 Read More »

Highlights from the week of 19 January - 26 January Ionis Pharmaceuticals ( EU, Approval ) European Commission approves Ionis and Otsuka's DAWNZERA for the prevention of recurrent hereditary angioedema attacks in patients aged 12 years and older GSK ( EU, Approval ) GSK’s vaccine, AREXVY, receives European Commission approval for expanded use in adults aged 18 years and older to prevent lower respiratory tract disease caused by RSV GSK ( NMPA, Approval ) NMPA approves GSK's TRELEGY ELLIPTA as the first and only single inhaler triple therapy for the maintenance treatment of both asthma and chronic obstructive pulmonary disease in adults Akesobio ( NMPA, Approval ) Akeso gains NMPA approval for its sNDA AK-111, a monoclonal antibody, to treat active ankylosing spondylitis All logos and trademarks remain the intellectual properties of their respective owners

📢Highlights from the Week of 19th January – 26th January in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢Highlights from the Week of 19th January – 26th January in the world of pharma and healthcare! 🗞️👀 Read More »

44th Annual J.P. Morgan Healthcare Conference Jan 12,2026 To Jan 14,2026 Jan 12 Jan 13 Jan 14 All logos and trademarks remain the intellectual properties of their respective owners

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of Jan 12,2026 To Jan 14,2026 💻

Uncategorized / YASHASWINI N

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of Jan 12,2026 To Jan 14,2026 💻 Read More »

pharma Business Intelligence & Strategic Consulting

📢Highlights from the Week of 1st January 2026 to 12th January 2026 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢Highlights from the Week of 1st January 2026 to 12th January 2026 in the world of pharma and healthcare! 🗞️👀 Read More »

← Previous 1 … 4 5 6 … 14 Next →

Search

Recent Posts

Highlights from the Week of 22nd June – 29th June in the world of pharma and healthcare!
Highlights from the Week of 15th June – 22nd June in the world of pharma and healthcare!
Today, June 21, is World ALS Day. Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, impairing a person’s ability to move, speak, and breathe. Raising awareness isn’t just about acknowledging the disease; it’s about advocating for better care, funding critical research, and fostering inclusive communities. Let’s use our platforms today to amplify the voices of those living with ALS/MND and support the scientists working tirelessly toward a cure. 💡
Shining a light on World Sickle Cell Day. Today, we stand in solidarity with the millions of individuals globally managing sickle cell disease. Raising awareness is just the first step—driving equitable access to healthcare, advancing clinical research, and fostering inclusive environments are where real change happens. Let’s commit to being a part of the solution. 🩸❤️
Today, our team stands in solidarity with the global community on World Kidney Cancer Day. Renal Cell Carcinoma (RCC) impacts hundreds of thousands of families worldwide every year.”Awareness is the first line of defense. By amplifying the conversation around Renal Cell Carcinoma, we empower individuals to take charge of their health before it’s too late.”This year, our emphasis is on supporting the emotional well-being of patients and caregivers bearing the psychological burden of this disease. Let’s break the silence, encourage proactive health check-ups, and foster a more supportive environment for everyone affected by kidney cancer.🧡 Check in on your loved ones, prioritize your metabolic health, and let’s spread awareness together.

Recent Comments

No comments to show.

Archives

June 2026
May 2026
April 2026
March 2026
February 2026
January 2026
December 2025
November 2025
October 2025
September 2025
August 2025
July 2025
June 2025
May 2025
April 2025
March 2025
February 2025
January 2025

Categories

Uncategorized

The Pharma BI division of

Vyuhgenics Inc.

Henderson, Nevada, USA – 89014

Vyuhpharma ®, All Rights Reserved.

Sitemap

Terms of use

Connect with us

Please fill in the information below, and we'll get back to you.

Full Name

Email Address

Your Company

Contact

Your message